The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.

ABSTRACT:

Objectives

: Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients with psychosis or agitation receive open treatment with risperidone for 16 weeks. Responders are randomized, double-blind, to one of three arms in Phase B: 1) continuation risperidone for the next 32 weeks, 2) risperidone for the next 16 weeks followed by placebo for 16 weeks, or 3) placebo for the next 32 weeks.

Methods

: Several design fea

SUBMITTER: Devanand DP 

PROVIDER: S-EPMC3146556 | biostudies-literature | 2012 Apr

REPOSITORIES: biostudies-literature